Zobrazeno 1 - 10
of 12 456
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Sebastian F. Schoppmann, Emmanuella Guenova, Gerd Jomrich, Matthias Preusser, Robin Ristl, Dariga Ramazanova, Aysegül Ilhan-Mutlu, Richard Grose, Christina Fassnacht, Dagmar Kollmann, Yi-Chien Tsai
Publikováno v:
European Journal of Surgical Oncology. 48:383-390
The effects of cytotoxic chemotherapy on the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in cancer cells and peritumoral cells are unclear. The aim of this study was to investigate the impact of neoadjuvant chemotherapy on PD-
Autor:
Marie-Jeanne T. F. D. Vrancken Peeters, Marjolein L. Smidt, Sabine R. de Wild, Janine M Simons, Linetta B. Koppert
Publikováno v:
Clinical Breast Cancer, 22(1), e59-e64. Elsevier
Clinical Breast Cancer, 22(1), E59-E64. CIG Media Group, L.P.
Clinical Breast Cancer, 22(1), E59-E64. CIG Media Group, L.P.
In node positive breast cancer patients who are treated with neoadjuvant systemic therapy, axillary staging and treatment is still a topic of debate. This multicenter study will contribute to evidence-based guidelines with regard to the oncologic saf
Autor:
Satoshi Koyama, Taihei Fujii, Hiromi Takeuchi, Tsuyoshi Morisaki, Takahiro Fukuhara, Kazunori Fujiwara, Yosuke Nakamura
Publikováno v:
Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus. Auris Nasus Larynx. 48(6), 1189-1192. 2020-07-16.
Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor prognosis because of frequent lymph node invasion and
Autor:
Thilo Welsch, Sebastián García, Marius Distler, Felix Merboth, Jürgen Weitz, Daniel E. Stange, Janusz von Renesse
Publikováno v:
Oncology Research and Treatment. 45:45-53
Introduction: Patients with advanced gastric cancer (AGC) frequently show peritoneal carcinomatosis (PC). PC reduces life expectancy and quality of life. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been show
Autor:
M. Faehling, Frank Heinzelmann, Rainer Sätzler, Susanne Martina Eschmann, Jörn Sträter, Sabine Fallscheer, Sebastian Kramberg
Publikováno v:
European Journal of Cancer. 156:175-186
Background Recent phase II–III trials of immuno(chemo)therapy before resection in locally advanced resectable non-small cell lung cancer (NSCLC) report high rates of pathological response and promising survival. However, primarily, patients who did
Publikováno v:
European Journal of Surgical Oncology. 47:2460-2464
Introduction The induction of adaptive cellular immunity in patients with in-transit melanoma metastasis treated with hyperthermic isolated limb perfusion (ILP) with melphalan has been shown to contribute to the effectiveness of the therapy. Activate
Publikováno v:
Anti-Cancer Drugs
OBJECTIVE A retrospective study was conducted to analyze which translational therapy, palliative chemotherapy and surgery is the best treatment for locally advanced and advanced pancreatic cancer, and to screen out the dominant population for the bes